medaka strain gu, albino mutant medaka strain i-3, leucophore deficient mutant medaka strain 1f and medaka FLF strain which is deficient in leucophores in the female.

6. (Twice amended) A see-through medaka wherein said medaka is produced by further selective mating between the see-through medaka according to claim 3 and a see-through mekaka produced by repeated selective mating between iridophore deficient mutant medaka strain gu, albino mutant medaka strain i-3, leucophore deficient mutant medaka strain 1f, and medaka FLF strain which is deficient in leucophores in the female.

7. (Twice amended) A transgenic see-through medaka deficient in iridophores, melanophores, xanthophores and leucophores, having in its genome a transgene being a fusion of a promoter of a gene which expresses specifically in a specific organ, with a coding region of a gene encoding a fluorescent protein, wherein said fluorescent protein is expressed specifically in said organ.

8. (Twice amended) A transgenic see-through medaka produced by further selective mating between the see-through medaka according to claim 2 and iridophore deficient mutant medaka strain il-1, having in its genome a transgene being a fusion of a promoter of a gene which expresses specifically in a specific organ, with a coding region of a gene encoding a fluorescent protein, wherein said fluorescent protein is expressed specifically in said organ.

9. (Twice amended) A transgenic see-through medaka deficient in iridophores, melanopores and xanthophores, wherein the sex of said medaka can be identified by the presence or absence of leucophores and/or a DNA marker, having in its genome a transgene being a fusion of a promoter of a gene which expresses specifically

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

in a specific organ, with a coding region of a gene encoding a fluorescent protein, wherein said fluorescent protein is expressed specifically in said organ.

10. (Twice amended) A transgenic see-through medaka produced by further selective mating between the see-through medaka according to claim 3 and a see-through medaka produced by repeated selective mating between iridophore deficient mutant medaka strain gu, albino mutant medaka strain i-3, leucophore deficient mutant medaka strain 1f, and medaka FLF strain which is deficient in leucophores in the female, having in its genome a transgene being a fusion of a promoter of a gene which expresses specifically in a specific organ, with a coding region of a gene encoding a fluorescent protein, wherein said fluorescent protein is expressed specifically in said organ.

23. (Amended) A transgenic see-through medaka produced by repeated selective mating between iridophore deficient mutant medaka strain gu, albino mutant medaka strain i-3 and leucophore deficient mutant medaka strain 1f, having in its genome a transgene being a fusion of a promoter of a gene which expresses specifically in a specific organ, with a coding region of a gene encoding a fluorescent protein, wherein said fluorescent protein is expressed specifically in said organ.

24. (Amended) A transgenic see-through medaka produced by repeated selective mating between iridophore deficient mutant medaka strain gu, albino mutant medaka strain i-3, leucophore deficient mutant medaka strain 1f and medaka FLF strain which is deficient in leucophores in the female, having in its genome a transgene being a fusion of a promoter of a gene which expresses specifically in a specific organ, with a coding region of a gene encoding a fluorescent protein, wherein said fluorescent protein is expressed specifically in said organ.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com